Zoli 0.05% Nasal Drops: Each mL of nasal drops contains Oxymetazoline Hydrochloride USP 0.5 mg. Zoli 0.025% Paediatric Nasal Drops: Each mL of nasal drops contains Oxymetazoline Hydrochloride USP 0.25 mg. The preservative used is Benzalkonium Chloride Solution BP 0.01%, and the vehicle is Water for Injection USP.
Oxymetazoline is used for its vasoconstrictor properties, acting on α-adrenoreceptors. When applied topically to the nasal mucosa, it causes vasoconstriction of the arterioles, reducing blood flow and diminishing mucosal swelling. This results in improved patency of the airways and better drainage of the sinuses.
Zoli Nasal Drops are indicated for nasal congestion associated with allergic and infectious rhinitis, sinusitis, and the common cold.
A dosage of 2–3 drops should be instilled into each nostril twice daily. The drops should be administered one nostril at a time while maintaining a head-low position to minimize the risk of swallowing the solution. The treatment duration should not exceed 3–5 days, and under no circumstances should it be continued for longer than 2 weeks.
Possible side effects include stinging, discomfort, or dryness in the nose, which occur infrequently. Headache has also been reported. Prolonged use can lead to rebound vasodilatation, also known as drug-induced rhinitis. Overuse may result in sedation in children. Additionally, Oxymetazoline may cause a short-lived rise in blood pressure, followed by prolonged hypotension and sedation.
Children under 5 years of age should not use Zoli 0.05% Nasal Drops. However, children aged 2–5 years can use Zoli 0.025% Paediatric Nasal Drops.
Oxymetazoline may cause a hypertensive crisis if used concurrently with MAO inhibitors or tricyclic antidepressants.
The product should be stored at a temperature not exceeding 30°C in a dry place and should be protected from light.
Medicine: Keep out of reach of children.